The New Zealand Government is spending $24 million on science aimed at producing practical results in health and business, with the money going toward AI and biotechnology research, according to a Beehive announcement.

Prime Minister Christopher Luxon has been building a broader push around this idea since the start of 2025. In his State of the Nation address in January, Luxon said he wants New Zealand to turn its ideas into products and money — so the science system delivers real benefits to people, not just papers and reports. He returned to that theme in May, telling a BusinessNZ audience he expected sharper focus on commercialisation, stronger links between researchers and business, and faster adoption of innovation from overseas.

The $24 million is the concrete number. What exactly the money funds — which agencies run the programmes, which AI or biotech areas get priority, and what success looks like — is not yet laid out in public material. That detail matters for understanding whether the investment will actually work.

The Government has been reshaping the science system more broadly. Luxon signalled early in his term that he sees bureaucracy and inertia as problems to fix. In January 2025 he told Parliament the Government would target what he called a culture of "no" — through faster consenting rules and resource management reform. Applied to science, that suggests the Government sees red tape and slow decision-making, not just money, as barriers to turning research into products.

New Zealand's science system has historically been good at research quality but poor at converting that research into commercial products and income. This gap is well-documented. It featured in a 2011 review of the state-funded research institutes and has cropped up repeatedly in science strategies ever since. Luxon is not the first prime minister to spot this problem, but he is placing a specific bet: directing public money toward AI and biotech, combined with pushing the research sector to focus on commercialisation, will succeed where previous cycles of strategy and spending have not.

Trade and investment with China figure in the picture too. Original reporting from the Asia Media Centre noted Luxon has been talking up AI and China ties at a China Business Summit, which connects this domestic science spending to wider trade and foreign investment priorities. A New Zealand science system with a sharper commercial focus becomes a more attractive partner for technology-focused investment from overseas — including from entities with China connections — though this relationship comes with political and security complexities the Government has handled with care so far.

The three threads — the $24 million, the commercialisation messaging, and the China business engagement — fit together logically. Whether $24 million is actually enough to shift how researchers work is another question. Crown-funded science in New Zealand runs across universities, state research institutes, and independent organisations, each with their own incentives and ways of doing things. Getting researchers to focus on commercial outcomes has proven hard to achieve through money alone; the research culture and how intellectual property is managed matter just as much.

What the Government has done is put funding and consistent prime ministerial backing behind this direction. As with past science strategies, the real test will be whether the practical settings — how funding is awarded, what researchers are expected to achieve, and the commercial rules they work within — actually change, or whether the money simply flows through existing systems with new labels.

---

Key takeaways

• The Government is investing $24 million in AI and biotech research aimed at producing commercial results.
• Prime Minister Luxon has made "commercialisation" — turning research into products and income — a priority since January 2025.
• New Zealand has historically been strong at research quality but weak at converting that research into commercial revenue.
• Money alone may not be enough; the research culture and how institutions operate also need to shift.
• China relationships and trade are part of the wider picture, though details remain limited.